arsenic trioxide has been researched along with cardiovascular agents in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, Z; Fu, J; Gong, Y; Jin, L; Li, B; Sun, M; Yang, B; Zhang, K; Zhang, Y; Zhao, X | 1 |
| Carcelero San Martín, E; Creus Baró, N; Riu Viladoms, G | 1 |
2 other study(ies) available for arsenic trioxide and cardiovascular agents
| Article | Year |
|---|---|
Arsenic trioxide-induced hERG K(+) channel deficiency can be rescued by matrine and oxymatrine through up-regulating transcription factor Sp1 expression.
Topics: Action Potentials; Alkaloids; Animals; Arsenic Trioxide; Arsenicals; Cardiovascular Agents; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; In Vitro Techniques; Matrines; Myocytes, Cardiac; Oxides; Patch-Clamp Techniques; Promoter Regions, Genetic; Quinolizines; Sp1 Transcription Factor; Up-Regulation | 2013 |
Severe myopericarditis following induction therapy with idarubicin and transretinoic acid in a patient with acute promyelocytic leukemia.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Cardiovascular Agents; Chest Pain; Drug Substitution; Echocardiography; Electrocardiography; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Myocarditis; Pericarditis; Remission Induction; Tretinoin | 2018 |